Oncolytics Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oncolytics Biotech (ONCY).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$5Upside to Avg. PT+618.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 19, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Cut	Buy	$10→$5
May 26, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$10
Nov 17, 2025	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$5→$10
Aug 13, 2025	Lake Street	Chad Messer	Initiate	Buy	$7
May 21, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
May 16, 2025	Jones Trading	Soumit Roy	Downgrade	Buy→Hold	—
Mar 10, 2025	Maxim Group	Jason McCarthy	PT Cut	Buy	$5→$3
Mar 10, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Mar 10, 2025	RBC Capital	Douglas Miehm	PT Cut	Outperform	$6→$5
Feb 3, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Nov 14, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Sep 19, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Aug 21, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
May 14, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Apr 4, 2024	Raymond James	Rahul Sarugaser	Initiate	Outperform	$3
Mar 8, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Feb 14, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Jan 19, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Jan 4, 2024	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
Nov 13, 2023	HC Wainwright & Co.	Patrick Trucchio	PT Cut	Buy	$15→$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Watching Oncolytics Biotech; Zacks Small-Cap Research Gives Stock $6 Price Valuation

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Raises Price Target to $10

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and raises the price target from $5 to $10.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Oncolytics Biotech with Buy Rating, Announces Price Target of $7

Lake Street analyst Chad Messer initiates coverage on Oncolytics Biotech (NASDAQ:ONCY) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.

Benzinga Newsdesk

Oncolytics Biotech Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Oncolytics Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

PRO
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price Target

PRO
Watching Oncolytics Biotech; Zacks Small-Cap Research Gives Stock $6 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Raises Price Target to $10

PRO
Lake Street Initiates Coverage On Oncolytics Biotech with Buy Rating, Announces Price Target of $7

PRO
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target

People Also Watch

People Also Watch

Oncolytics Biotech Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Oncolytics Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

PROHC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price Target

PROWatching Oncolytics Biotech; Zacks Small-Cap Research Gives Stock $6 Price Valuation

PROHC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Raises Price Target to $10

PROLake Street Initiates Coverage On Oncolytics Biotech with Buy Rating, Announces Price Target of $7

PROHC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

PRO
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price Target

PRO
Watching Oncolytics Biotech; Zacks Small-Cap Research Gives Stock $6 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Raises Price Target to $10

PRO
Lake Street Initiates Coverage On Oncolytics Biotech with Buy Rating, Announces Price Target of $7

PRO
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target